The estimated Net Worth of Karen Bernstein is at least $95.5 Tysiąc dollars as of 16 February 2023. Karen Bernstein owns over 8,750 units of Ovid Therapeutics Inc stock worth over $9,800 and over the last 7 years he sold OVID stock worth over $0. In addition, he makes $85,714 as Independent Director at Ovid Therapeutics Inc.
Karen has made over 3 trades of the Ovid Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of OVID stock worth $9,800 on 16 February 2023.
The largest trade he's ever made was buying 10,000 units of Ovid Therapeutics Inc stock on 26 February 2019 worth over $20,200. On average, Karen trades about 1,513 units every 87 days since 2017. As of 16 February 2023 he still owns at least 8,750 units of Ovid Therapeutics Inc stock.
You can see the complete history of Karen Bernstein stock trades at the bottom of the page.
Dr. Karen Bernstein Ph.D. serves as Independent Director of the Company. Dr. Bernstein co-founded BioCentury Inc., or BioCentury, a provider of clinical, regulatory and finance news for the biotechnology and pharmaceutical industries, where she served as Editor-in-Chief from its inception in August 1992 to August 2015. Dr. Bernstein currently serves on the board of directors of Achaogen, Inc., a publicly held biopharmaceutical company. She previously served on the board of directors of Vitae Pharmaceuticals, Inc., which was acquired by Allergan Holdco US, Inc. Dr. Bernstein continues to serve as Chairman of the board of director BioCentury, Inc. Dr. Bernstein earned her BA in Politics and History from Brandeis University and her PhD in Political Science from Stanford University. Bernstein’s extensive knowledge of the life science industry qualifies her to serve on our Board.
As the Independent Director of Ovid Therapeutics Inc, the total compensation of Karen Bernstein at Ovid Therapeutics Inc is $85,714. There are 8 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.
Karen Bernstein is 67, he's been the Independent Director of Ovid Therapeutics Inc since 2015. There are 3 older and 12 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
Karen's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK, NY, 10001.
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan oraz Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: